Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optical coherence tomography-based assessment of retinal vascular pathology in cerebral small vessel disease.

Neurological research and practice·2020
Same author

Necrosome-positive granulovacuolar degeneration is associated with TDP-43 pathological lesions in the hippocampus of ALS/FTLD cases.

Neuropathology and applied neurobiology·2020
Same author

Recent silent infarcts do not increase the risk of haemorrhage after intravenous thrombolysis.

European journal of neurology·2020
Same author

Statins, diabetes mellitus and prognosis of amyotrophic lateral sclerosis: data from 501 patients of a population-based registry in southwest Germany.

European journal of neurology·2020
Same author

[Gene-specific treatment of neurological diseases-current state and perspectives].

Der Nervenarzt·2020
Same author

[Gene-specific treatment approaches in amyotrophic lateral sclerosis in the present and future].

Der Nervenarzt·2020

Related Experiment Video

Updated: May 30, 2026

Eye-Tracking Control to Assess Cognitive Functions in Patients with Amyotrophic Lateral Sclerosis
07:00

Eye-Tracking Control to Assess Cognitive Functions in Patients with Amyotrophic Lateral Sclerosis

Published on: October 13, 2016

[German consortium for frontotemporal lobar degeneration].

M Otto1, A C Ludolph, B Landwehrmeyer

  • 1Klinik für Neurologie, Universität Ulm, Oberer Eselsberg 35, 89081 Ulm, Deutschland. markus.otto@uni-ulm.de

Der Nervenarzt
|August 2, 2011
PubMed
Summary

Frontotemporal lobar degeneration (FTLD) encompasses diverse neurodegenerative disorders. Research is advancing neuropathological understanding and aims to develop early diagnostic and therapeutic parameters for FTLD spectrum conditions.

More Related Videos

The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease
15:09

The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease

Published on: October 3, 2012

Related Experiment Videos

Last Updated: May 30, 2026

Eye-Tracking Control to Assess Cognitive Functions in Patients with Amyotrophic Lateral Sclerosis
07:00

Eye-Tracking Control to Assess Cognitive Functions in Patients with Amyotrophic Lateral Sclerosis

Published on: October 13, 2016

The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease
15:09

The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease

Published on: October 3, 2012

Area of Science:

  • Neuroscience
  • Neuropathology
  • Genetics

Context:

  • Frontotemporal lobar degeneration (FTLD) is a complex group of neurodegenerative disorders.
  • The FTLD spectrum includes frontotemporal dementia (FTD), primary non-fluent aphasia (PNFA), semantic dementia, amyotrophic lateral sclerosis with FTD (ALS-FTD), corticobasal syndrome (CBS), and progressive supranuclear palsy (PSP).

Purpose:

  • To summarize current understanding of the FTLD spectrum.
  • To highlight advances in neuropathological classification based on protein accumulations (FTLD-tau, FTLD-TDP43, FTLD-FUS).
  • To underscore the need for early diagnostic and objective therapeutic parameters.

Summary:

  • FTLD classification has evolved, now encompassing a broader spectrum of clinical and pathological entities.
  • Neuropathological definitions are refined by identifying specific protein aggregates, primarily tau and TDP-43.
  • Current therapeutic strategies are limited, emphasizing the need for improved diagnostic tools.

Impact:

  • Enhanced understanding of FTLD heterogeneity.
  • Foundation for developing novel diagnostic biomarkers for early detection and monitoring.
  • Potential to guide the development of targeted therapeutic interventions for FTLD.